PEDIATRICS Vol. 100 No. 1 July 1997, pp. 24-30
Safety and Pharmacokinetics of Multiple Doses of Recombinant Human CuZn Superoxide Dismutase Administered Intratracheally to Premature Neonates With Respiratory Distress Syndrome
Received Sep 23, 1996; accepted Nov 18, 1996.
,
,,
From the * Departments of Pediatrics (Neonatology), ** Radiology,
Biostatistics, and || CardioPulmonary Research Institute,
Winthrop-University Hospital, SUNY Stony Brook School of Medicine,
Mineola, NY; Brigham and Women's Hospital, Harvard Medical School,
Boston, MA; § University of Maryland Medical Center, Baltimore MD;
Thomas Jefferson University Medical Center, Philadelphia, PA;
¶ University of Alabama at Birmingham, Birmingham, AL; # Children's
Healthcare-Minneapolis, Minneapolis, MN; and §§ Bio-Technology General
Corp, Iselin, NJ; for the North American rhSOD Study Group.
Objectives. To examine the safety and pharmacokinetics of multiple intratracheal (IT) doses of recombinant human CuZn superoxide dismutase (rhSOD) in premature infants with respiratory distress syndrome who are at risk for developing bronchopulmonary dysplasia (BPD).
Methods. Thirty-three infants (700 to 1300 g) were randomized and blindly received saline, 2.5 mg/kg or 5 mg/kg rhSOD IT within 2 hours of surfactant administration. Infants were treated every 48 hours (as long as endotracheal intubation was required) up to 7 doses. Serial blood and urine studies, chest radiographs, neurosonograms, SOD concentration and activity measurements, and tracheal aspirate (TA) inflammatory markers were assessed throughout the 28-day study.
Results. SOD concentrations in serum (0.1 [0.05/0.15] µg/mL-geometric mean with lower/upper confidence intervals), tracheal aspirates (TA) (0.2 [0.1/0.3] µg/mL) and urine (0.3 [0.2/0.4] µg/mL) were similar at baseline in all 3 groups and did not change significantly in the placebo group. In the rhSOD treatment groups, SOD concentrations were increased on day 3 and did not change significantly thereafter over the 14-day dosing period (also measured on days 5, 7, and 13). SOD concentrations averaged 0.4 [0.3/0.5] µg/mL in serum, 0.8 [0.6/1.2] µg/mL in TA and 1.1 [1.0/1.3] µg/mL in urine for the low-dose group and 0.6 [0.5/0.7] µg/mL in serum, 1.1 [0.9/1.5] µg/mL in TA, and 2.2 [1.6/2.9] µg/mL in urine for the high-dose group over the 14-day dosing period. Enzyme activity directly correlated with SOD concentration and rhSOD was active even when excreted in urine. TA markers of acute lung injury (neutrophil chemotactic activity, albumin concentration) were lower in the rhSOD agroups compared with placebo. No significant differences in any clinical outcome variable were noted between groups.
Conclusions. These data indicate that multiple IT doses of rhSOD increase the concentration and activity of the enzyme in serum, TA and urine, reduce TA lung injury markers and are well-tolerated. Further clinical trials examining the efficacy of rhSOD in the prevention of BPD are warranted.
Key words: antioxidants, superoxide dismutase, bronchopulmonary dysplasia, respiratory distress syndrome.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Gotz, A. Greenough, J. Grigg, et al. Medicines used in respiratory diseases only seen in children Eur. Respir. J., September 1, 2009; 34(3): 531 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhandari and V. Bhandari Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia Pediatrics, June 1, 2009; 123(6): 1562 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lakshminrusimha, J. A. Russell, S. Wedgwood, S. F. Gugino, J. A. Kazzaz, J. M. Davis, and R. H. Steinhorn Superoxide Dismutase Improves Oxygenation and Reduces Oxidation in Neonatal Pulmonary Hypertension Am. J. Respir. Crit. Care Med., December 15, 2006; 174(12): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-c. Koo, J. M. Davis, Y. Li, D. Hatzis, H. Opsimos, S. Pollack, M. S. Strayer, P. L. Ballard, and J. A. Kazzaz Effects of transgene expression of superoxide dismutase and glutathione peroxidase on pulmonary epithelial cell growth in hyperoxia Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L718 - L726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Arita, A. Joseph, H.-C. Koo, Y. Li, T. A. Palaia, J. M. Davis, and J. A. Kazzaz Superoxide dismutase moderates basal and induced bacterial adherence and interleukin-8 expression in airway epithelial cells Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1199 - L1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Mamo, H. B. Suliman, B.-L. Giles, R. L. Auten, C. A. Piantadosi, and E. Nozik-Grayck Discordant Extracellular Superoxide Dismutase Expression and Activity in Neonatal Hyperoxic Lung Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 313 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Davis, R. B. Parad, T. Michele, E. Allred, A. Price, and W. Rosenfeld Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase Pediatrics, March 1, 2003; 111(3): 469 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Ahmed, H. B. Suliman, R. J. Folz, E. Nozik-Grayck, M. L. Golson, S. N. Mason, and R. L. Auten Extracellular Superoxide Dismutase Protects Lung Development in Hyperoxia-exposed Newborn Mice Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 400 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. STEINHORN, G. ALBERT, D. D. SWARTZ, J. A. RUSSELL, C. R. LEVINE, and J. M. DAVIS Recombinant Human Superoxide Dismutase Enhances the Effect of Inhaled Nitric Oxide in Persistent Pulmonary Hypertension Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Avent, D. Coile, and L. Mathai Neonatal Chronic Lung Disease Journal of Pharmacy Practice, June 1, 2001; 14(3): 181 - 206. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Ilizarov, H.-C. Koo, J. A. Kazzaz, L. L. Mantell, Y. Li, R. Bhapat, S. Pollack, S. Horowitz, and J. M. Davis Overexpression of Manganese Superoxide Dismutase Protects Lung Epithelial Cells against Oxidant Injury Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 436 - 441. [Abstract] [Full Text]
|
|
